Atlas Trials

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Clinical trial NCT01264939 · COMPLETED

Trial details

NCT number
NCT01264939
Sponsor
Genentech, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Idiopathic Urticaria
Start date
2011-02-01
Primary completion
2012-11-01
Enrollment
336

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.